The vector of anti-CD19 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CD19. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD19 antibody linked to CD3-zeta signaling domains. And the vector product was designed for the treatment of chronic lymphoid leukemia.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
|CAR-LC381||Anti-CD19 (Denintuzumab) h(CD28-CD3ζ,iCasp-9, IL-15) Self-destruct CAR, pCDCAR1|
|CAR-LC012||Anti-CD19 (47G4) h(CD28-CD27-CD3ζ) CAR, pCDCAR1|
|VP-CAR-LC517||Lenti-CD19 CAR (scFv-CD27-CD3ζ, 47G4) Viral Particle|
|CAR-NK-2-M328-CZ||Anti-CD19 scFv h(b2c-CD3ζ) CARNK, pCDCAR1|
|VP-CAR-LC628||Lenti-CD19 CAR (scFv-41BB-CD3ζ, 104877) Viral Particle|
|CAR-NK-1-M328-Z||Anti-CD19 scFv h(CD3ζ) CARNK, pCDCAR1|
|CAR-LC232||Anti-CD19 (S2) h(41BB-CD3ζ) CAR, pCDCAR1|
|CAR-LC186||Anti-CD19 (Coltuximab) h(41BB-CD3ζ) CAR, pCDCAR1|
|CAR-LC274||Anti-CD19 h(CD28-OX40-CD3ζ, FKBP12/FRB) Conditional CAR, pCDCAR1|
|CAR-MZ052||Anti-CD19 scFv h(41BB-CD28-CD3ζ) CAR, pCDCAR1|
Copyright © 2007 - 2019 Creative Biolabs. All Rights Reserved